Previous 10 | Next 10 |
2024-05-09 11:09:34 ET More on Sensei Biotherapeutics Seeking Alpha’s Quant Rating on Sensei Biotherapeutics Historical earnings data for Sensei Biotherapeutics Financial information for Sensei Biotherapeutics Read the full article on Seeking Alpha ...
- Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities - - Company to present topline clinical data from the SNS-101 Phase 1 dose escalation study at the 2024 ASCO Annual Meeting - - Enrollment in the dose expansion...
2024-05-03 08:29:21 ET More on premarkets gainers & stock Zura Bio stock jumps on plans to raise $112.5M in private financing Financial information for Binah Capital Group, Inc. Financial information for Healthcare Triangle Seeking Alpha’s Quant Ra...
A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 30.3% to $0.2932 on volume of 173,918,707 shares Emergent Biosolutions Inc. (EBS) rose 71.0% to $3.3 on volume of 150,987,238 shares PROSHARES TRUST (SQQQ) fell 3.6% to $11.78 on volume of 136,332,744 sh...
2024-05-02 12:49:49 ET Gainers: Emergent Biosolutions EBS +96% . XBP Europe Holdings ( XBP ) +56% . Aspen Aerogels ASPN +52% . Syra Health Corp ( SYRA ) +47% . Safe & Green Holdings Corp SGBX +42% . Sensei Biotherapeutics ( SNSE ...
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that topline clinical data from the monotherapy and combin...
BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the publication of a peer-reviewed research paper in Nat...
BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate on a panel titled...
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that the company will present preclinical data on its cond...
- Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK profile both as monotherapy and in combination with PD-1 blockade - - Topline efficacy and biomarker data for both monotherapy and combination arms of dose escal...
News, Short Squeeze, Breakout and More Instantly...
Sensei Biotherapeutics Inc. Company Name:
SNSE Stock Symbol:
NASDAQ Market:
Sensei Biotherapeutics Inc. Website:
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 428.5% to $0.983 on volume of 924,758,481 shares Greenwave Technology Solutions Inc. (GWAV) fell 4.2% to $0.0849 on volume of 393,457,542 shares Netcapital Inc. (NCPL) rose 10.1% to $0.1925 on volum...
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) fell 5.3% to $0.0839 on volume of 148,968,464 shares Netcapital Inc. (NCPL) rose 66.0% to $0.2901 on volume of 111,713,040 shares Cue Health Inc. (HLTH) rose 33.6% to $0.126 on volume of 99,7...
- Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profile validate conditionally active approach - - Investor webcast to be held on Monday, June 3 at 8:00 a.m. ET - BOSTON, May 23, 2024 (GLOBE NEW...